SCHEMBL1821968

SCHEMBL1821968

CCCN1C(=O)c2ccccc2C1(OCc1cc(OC)c(O)c(OC)c1)c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 20/20 1.00
TP53 P04637 13/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29994301 1.00 MDM2 (1.00) MDM2TP53
SCHEMBL12085950 0.93 MDM2 (0.91) MDM2TP53
SCHEMBL4912370 0.92 TP53 (1.00) MDM2TP53
SCHEMBL4912373 0.92 TP53 (1.00) MDM2TP53
SCHEMBL18569316 0.92 MDM2 (0.87) MDM2TP53
SCHEMBL12083897 0.90 MDM2 (0.82) MDM2TP53
SCHEMBL12017315 0.90 MDM2 (0.82) MDM2TP53
SCHEMBL4917242 0.90 MDM2 (1.00) MDM2TP53
SCHEMBL4917235 0.90 MDM2 (1.00) MDM2TP53
SCHEMBL12083973 0.88 MDM2 (1.00) MDM2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2960233-B1 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECH LTD (GB) 2019-10-30 EP disclosed
US-10414726-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-09-17 US disclosed
US-20180118684-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
EP-1786773-B1 ISOINDOLIN-1-ONE DERIVATIVES CANCER RES TECH LTD (GB) 2017-03-01 EP disclosed
EP-1786773-B1 ISOINDOLIN-1-ONE DERIVATIVES CANCER RES TECH LTD (GB) 2017-03-01 EP disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-9358222-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-07 US disclosed
EP-2960233-A1 NEW THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2015-12-30 EP disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-8618158-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-12-31 US disclosed
US-8258175-B2 Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-09-04 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
EP-2315749-A2 NEW THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2011-05-04 EP disclosed
WO-2009156735-A2 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-30 WO disclosed
US-20080261917-A1 Isoindolin-1-One Derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2008-10-23 US disclosed
US-20080261917-A1 Isoindolin-1-One Derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2008-10-23 US disclosed
US-20080261917-A1 Isoindolin-1-One Derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2008-10-23 US disclosed
EP-1786773-A1 ISOINDOLIN-1-ONE DERIVATIVES Cancer Research Technology Limited (GB) 2007-05-23 EP disclosed
WO-2006024837-A1 ISOINDOLIN-1-ONE DERIVATIVES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-03-09 WO disclosed
WO-2006024837-A1 ISOINDOLIN-1-ONE DERIVATIVES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194486-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 MDM2 2/4885TP53 1/4885
US-20080261917-A1 Isoindolin-1-One Derivatives HCN3, NHERF1, SIGMAR1 MDM2 1568/4885TP53 2490/4885
US-20110224274-A1 New Therapeutic Agents TP53, MDM2, TP53BP1 MDM2 2/4885TP53 1/4885
US-20180118684-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 MDM2 2/4885TP53 1/4885
US-10414726-B2 Therapeutic agents TP53, MDM2, TP53BP1 MDM2 2/4885TP53 1/4885
US-20160355478-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 MDM2 2/4885TP53 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.